| scholarly article | Q13442814 |
| P50 | author | Paul E. Keck | Q111738411 |
| P2093 | author name string | Ronald Marcus | |
| Stavros Tourkodimitris | |||
| Aripiprazole Study Group | |||
| Mirza Ali | |||
| Gary Ingenito | |||
| Anutosh Saha | |||
| Amy Liebeskind | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| placebo | Q269829 | ||
| P304 | page(s) | 1651-1658 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | |
| P478 | volume | 160 |
| Q35833294 | A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder |
| Q36029842 | A Chromatographic Determination of Aripiprazole using HPLC and UPLC: A Comparative Validation Study |
| Q61886048 | A History of the Pharmacological Treatment of Bipolar Disorder |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q38027197 | A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania |
| Q37827220 | A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder |
| Q46170156 | A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder |
| Q48247071 | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). |
| Q47696307 | A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. |
| Q37166131 | A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder |
| Q37307014 | A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder |
| Q37510958 | A review of the safety and tolerability of aripiprazole |
| Q37531967 | A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole |
| Q41577831 | Acute akathisia with suicidal ideation associated with low dose aripiprazole. |
| Q35236966 | Acute and long-term treatment of mania. |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q34925151 | Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q40176997 | An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. |
| Q34553398 | Anticonvulsants and antipsychotics in the treatment of bipolar disorder |
| Q35073872 | Antimanic treatments in bipolar mixed states |
| Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
| Q33755676 | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
| Q37111491 | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review |
| Q24201765 | Aripiprazole alone or in combination for acute mania |
| Q37831357 | Aripiprazole for the treatment of bipolar disorder: a review of current evidence |
| Q57612470 | Aripiprazole in Bipolar Disorder |
| Q37797999 | Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group |
| Q48258866 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). |
| Q35717037 | Aripiprazole in the acute and maintenance phase of bipolar I disorder |
| Q28478032 | Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q37133284 | Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence |
| Q36026701 | Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. |
| Q35062649 | Aripiprazole in treating a manic episode associated with hydrocephalus: a case report |
| Q51765278 | Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. |
| Q35098039 | Aripiprazole maintenance increases smoked cocaine self-administration in humans |
| Q34655996 | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study |
| Q48793990 | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial |
| Q46547099 | Aripiprazole prescribing and continuation rates during psychiatric hospitalization |
| Q37827219 | Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness |
| Q34548876 | Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability |
| Q34375654 | Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. |
| Q37970762 | Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder |
| Q37581586 | Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder |
| Q26778312 | Aripiprazole: from pharmacological profile to clinical use |
| Q35747870 | Aripiprazole: in acute mania associated with bipolar I disorder |
| Q36808054 | Aripiprazole: pharmacology and evidence in bipolar disorder |
| Q34558285 | Aripiprazole: pharmacology, efficacy, safety and tolerability |
| Q38077281 | Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q36158824 | Atypical antipsychotics: newer options for mania and maintenance therapy |
| Q57738604 | Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika |
| Q28468613 | Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole |
| Q46587038 | Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38211511 | Clinical decision making in the treatment of mixed states |
| Q35936263 | Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies |
| Q37100104 | Comparison of mania patients suitable for treatment trials versus clinical treatment |
| Q34529810 | Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania |
| Q28686902 | Current and emerging therapies for the management of bipolar disorders |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q38586755 | Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder |
| Q38500850 | Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics |
| Q37135459 | Drugs and prolactin |
| Q83215397 | Easing the burden of bipolar disorder: from urgent situations to remission |
| Q36274272 | Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review |
| Q88404910 | Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study |
| Q46017126 | Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats. |
| Q42661585 | Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q34593776 | Efficacy and tolerability of pharmacotherapies for borderline personality disorder |
| Q38003197 | Efficacy of antimanic treatments in mixed states |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q35999567 | Efficacy of atypical antipsychotics in bipolar disorder |
| Q34994544 | Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q36364980 | Emerging treatments for bipolar disorder: safety and adverse effect profiles |
| Q34532071 | Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen |
| Q36881398 | Epidemiology, diagnosis and management of mixed mania |
| Q38259793 | Evaluating aripiprazole as a potential bipolar disorder therapy for adults |
| Q34296938 | Evidence-based options for treatment-resistant adult bipolar disorder patients |
| Q46984808 | Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials |
| Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
| Q36191013 | Higher than Physician's Desk Reference (US) doses on atypical antipsychotics |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q94561344 | Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics |
| Q34605085 | Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q36284465 | Management options for bipolar disorder in children and adolescents |
| Q58729864 | Medications that cause weight gain and alternatives in Canada: a narrative review |
| Q34365330 | Meta-analysis methods for risk differences |
| Q36664112 | Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial |
| Q38833165 | Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations |
| Q58834433 | Modeling of Hansen's solubility parameters of aripiprazole, ziprasidone, and their impurities: A nonparametric comparison of models for prediction of drug absorption sites |
| Q36119897 | Mood stabilization in the treatment of bipolar disorder: focus on quetiapine |
| Q43241336 | Movement disorders associated with aripiprazole use: a case series |
| Q37857918 | Multisite international collaborative clinical trials in mania |
| Q35872066 | New medication treatment options for bipolar disorders |
| Q35567382 | Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania |
| Q26783002 | Pharmacological Approaches for Treatment-resistant Bipolar Disorder |
| Q36936379 | Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials |
| Q36349023 | Pharmacological treatment of mixed states |
| Q36130303 | Pharmacotherapy of bipolar mixed states |
| Q44017165 | Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania |
| Q30462823 | Predictive animal models of mania: hits, misses and future directions |
| Q34600500 | Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents |
| Q36648780 | Psychopharmacology of pediatric bipolar disorder: a review |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q35875975 | Quality of life among bipolar disorder patients misdiagnosed with major depressive disorder |
| Q46788912 | Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q46744416 | Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic |
| Q35062881 | Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse |
| Q34595255 | Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study |
| Q51872425 | Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. |
| Q36780394 | Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial |
| Q36688973 | Role of aripiprazole in treating mood disorders |
| Q33587032 | Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). |
| Q36199036 | Safety and tolerability of emerging pharmacological treatments for bipolar disorder |
| Q35940851 | Safety considerations in pharmacotherapy of bipolar disorder |
| Q37202889 | Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. |
| Q33988376 | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review |
| Q37954416 | State of the art: treatment of bipolar disorders. |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q38352080 | Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists |
| Q64330025 | TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel |
| Q45282349 | Tardive dyskinesia and other movement disorders secondary to aripiprazole |
| Q48072363 | The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q26748677 | The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q36577856 | The metabolic effects of antipsychotic medications |
| Q35779335 | The pharmacology of bipolar disorder during pregnancy and breastfeeding |
| Q33619910 | The psychopathology and treatment of bipolar disorder |
| Q45070780 | The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research |
| Q24658110 | The role of lamotrigine in the management of bipolar disorder |
| Q36235502 | The safety and tolerability of atypical antipsychotics in bipolar disorder |
| Q37468555 | The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder |
| Q42164457 | Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q39048607 | Treating mixed mania/hypomania: a review and synthesis of the evidence |
| Q41528294 | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
| Q34769873 | Treatment of Acute Mania With Aripiprazole in an Older Adult With Noted Improvement in Coexisting Parkinson's Disease |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q37973144 | Treatment of mixed bipolar states |
| Q37665567 | Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q33932148 | Use pattern and off-label use of atypical antipsychotics in bipolar disorder, 1998-2002 |
| Q37428054 | Waterborne aripiprazole blunts the stress response in zebrafish |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q27014860 | When to start aripiprazole therapy in patients with bipolar mania |
| Q46727012 | Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy |
| Q35022930 | Women and bipolar disorder across the life span |
| Q86485574 | Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort |
| Q36938311 | Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder |
| Q46202394 | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study |
Search more.